Related references
Note: Only part of the references are listed.Inhibitors of Na+/K+ ATPase exhibit antitumor effects on multicellular tumor spheroids of hepatocellular carcinoma
Yeonhwa Song et al.
SCIENTIFIC REPORTS (2020)
Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
Alison L. Raybould et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2020)
3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications
Volker M. Lauschke et al.
BIOTECHNOLOGY JOURNAL (2019)
Mutant p53 improves cancer cells' resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6
Dania Sicari et al.
ONCOGENE (2019)
Immunotherapy for hepatocellular carcinoma: Current and future
Michael P. Johnston et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Argininosuccinate synthetase 1 contributes to gastric cancer invasion and progression by modulating autophagy
Chung-Ying Tsai et al.
FASEB JOURNAL (2018)
Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
Mohamed Bouattour et al.
HEPATOLOGY (2018)
Patient-derived multicellular tumor spheroids towards optimized treatment for patients with hepatocellular carcinoma
Yeonhwa Song et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Immune checkpoint therapy in liver cancer
Feng Xu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Targets for immunotherapy of liver cancer
Tim F. Greten et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Influence of the Tumor Microenvironment on Cancer Cells Metabolic Reprogramming
Victoire Gouirand et al.
FRONTIERS IN ONCOLOGY (2018)
Tumor Microenvironment and Metabolism
Li V. Yang
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Implication of the Hedgehog pathway in hepatocellular carcinoma
Carminia Maria Della Corte et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53
Takafumi Miyamoto et al.
SCIENCE ADVANCES (2017)
Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo
Lin Liu et al.
CANCER BIOLOGY & THERAPY (2017)
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Yan-jing Zhu et al.
ACTA PHARMACOLOGICA SINICA (2017)
Molecular Pathways: Immunosuppressive Roles of IRE1α-XBP1 Signaling in Dendritic Cells of the Tumor Microenvironment
Juan R. Cubillos-Ruiz et al.
CLINICAL CANCER RESEARCH (2016)
The Role of the PERK/eIF2 alpha/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress
W. Rozpedek et al.
CURRENT MOLECULAR MEDICINE (2016)
Arginine deprivation induces endoplasmic reticulum stress in human solid cancer cells
Yaroslav Bobak et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2016)
Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma
Dario Barbone et al.
PLOS ONE (2016)
Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1a, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation
Yan Long et al.
ONCOTARGET (2016)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
Amino acid management in cancer
Zhi-Yang Tsun et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2015)
Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines
Yan-Shen Shan et al.
SCIENTIFIC REPORTS (2015)
Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis
Guangchao Cao et al.
MEDICAL SCIENCE MONITOR (2015)
Transforming Growth Factor-β as a Therapeutic Target in Hepatocellular Carcinoma
Gianluigi Giannelli et al.
CANCER RESEARCH (2014)
Serine and glycine metabolism in cancer
Ivano Amelio et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance
Hsuan-Ying Huang et al.
CLINICAL CANCER RESEARCH (2013)
Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma
Lina Wu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
A regulatory role of Kruppel-like factor 4 in endothelial argininosuccinate synthetase 1 expression in response to laminar shear stress
Gyeong In Mun et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
The unfolded protein response: controlling cell fate decisions under ER stress and beyond
Claudio Hetz
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis
B. Delage et al.
CELL DEATH & DISEASE (2012)
Endothelial Argininosuccinate Synthetase 1 Regulates Nitric Oxide Production and Monocyte Adhesion under Static and Laminar Shear Stress Conditions
Gyeong In Mun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
HCC and angiogenesis: possible targets and future directions
Andrew X. Zhu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer
Barbara Delage et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Glutamine addiction: a new therapeutic target in cancer
David R. Wise et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab
Richard S. Finn et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9
Jing-song Chen et al.
HEPATOLOGY RESEARCH (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
CHOP Mediates Endoplasmic Reticulum Stress-Induced Apoptosis in Gimap5-Deficient T Cells
Steven C. Pino et al.
PLOS ONE (2009)
Arginine and glycine stimulate creatine synthesis in creatine transporter 1-deficient lymphoblasts
Vincenzo Leuzzi et al.
ANALYTICAL BIOCHEMISTRY (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Aberrant regulation of argininosuccinate synthetase by TNF-α in human epithelial ovarian cancer
Peter W. Szlosarek et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates
Wenjuan Shi Jobgen et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2006)
Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma
PNM Cheng et al.
CANCER LETTERS (2005)
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers - A method for identifying cancers sensitive to arginine deprivation
BJ Dillon et al.
CANCER (2004)
CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum
SJ Marciniak et al.
GENES & DEVELOPMENT (2004)
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
T Takahashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
